{"name":"Teva Branded Pharmaceutical Products R&D LLC","slug":"teva-branded-pharmaceutical-products-rd-llc","ticker":"","exchange":"","domain":"tevabrandedproductsrdllc.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":5,"colorKey":"oncology","drugs":[{"name":"TEV-48574 Dose Regimen A","genericName":"TEV-48574 Dose Regimen A","slug":"tev-48574-dose-regimen-a","indication":"Other","status":"phase_2"},{"name":"TEV-48574 Dose Regiment B","genericName":"TEV-48574 Dose Regiment B","slug":"tev-48574-dose-regiment-b","indication":"Other","status":"phase_2"},{"name":"TEV-53408","genericName":"TEV-53408","slug":"tev-53408","indication":"Other","status":"phase_2"},{"name":"TEV-56286 Reference","genericName":"TEV-56286 Reference","slug":"tev-56286-reference","indication":"Other","status":"phase_1"},{"name":"TEV-56286 Test","genericName":"TEV-56286 Test","slug":"tev-56286-test","indication":"Other","status":"phase_1"}]},{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"TV-44749","genericName":"TV-44749","slug":"tv-44749","indication":"Osteoarthritis pain","status":"phase_3"}]}],"pipeline":[{"name":"TEV-48574 Dose Regimen A","genericName":"TEV-48574 Dose Regimen A","slug":"tev-48574-dose-regimen-a","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"TV-44749","genericName":"TV-44749","slug":"tv-44749","phase":"phase_3","mechanism":"TV-44749 is a selective inhibitor of transient receptor potential vanilloid 1 (TRPV1) that reduces pain signaling by blocking capsaicin-sensitive nociceptors.","indications":["Osteoarthritis pain","Neuropathic pain"],"catalyst":""},{"name":"TEV-48574 Dose Regiment B","genericName":"TEV-48574 Dose Regiment B","slug":"tev-48574-dose-regiment-b","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"TEV-53408","genericName":"TEV-53408","slug":"tev-53408","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"TEV-56286 Reference","genericName":"TEV-56286 Reference","slug":"tev-56286-reference","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"TEV-56286 Test","genericName":"TEV-56286 Test","slug":"tev-56286-test","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":6,"phaseCounts":{"phase_2":3,"phase_3":1,"phase_1":2},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}